Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma.
|
| Abstract |
Platelet-derived growth factor receptors (PDGFRs) are now considered promising targets for the treatment of osteosarcoma. Herein, the design, synthesis, and structure-activity relationships (SAR) of novel pyrimidine-2,4-diamine derivatives that selectively inhibit PDGFRα/β kinases have been studied. The screening cascades revealed that 7m was the preferred compound among these derivatives, with IC50 values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. Moreover, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) experiment revealed that 7m has a substantial cytotoxic effect against all osteosarcoma cancer cell lines; 7m also displayed robust antitumor effects and low toxicity in a xenograft model. Additionally, 7m showed excellent bioavailability (F = 62.9%), suitable half-life (T1/2 = 2.12 h), satisfactory metabolic stability, and weak CYP isoform inhibitory activity, suggesting that 7m is a potential drug candidate for PDGFR-driven osteosarcoma.
|
|---|---|
| Authors | Xiaojing Chen, Lu Liu, Peng Liu, Yingying Chen, Dan Lin, Hao Yan, Qi Yan, Yi Wang, Yinda Qiu, Bo Fang, Huijing Huang, Jianchang Qian, Yunjie Zhao, Zhou Du, Qianwen Zhang, Xiaokun Li, Xiaohui Zheng, Zhiguo Liu |
| Journal | Journal of medicinal chemistry (J Med Chem) Vol. 65 Issue 7 Pg. 5374-5391 (04 14 2022) ISSN: 1520-4804 [Electronic] United States |
| PMID | 35239349 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!